ADAG vs. VSTM, CGEN, CUE, XLO, IPHA, YMAB, FULC, CDMO, KALV, and NGNE
Should you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Verastem (VSTM), Compugen (CGEN), Cue Biopharma (CUE), Xilio Therapeutics (XLO), Innate Pharma (IPHA), Y-mAbs Therapeutics (YMAB), Fulcrum Therapeutics (FULC), Avid Bioservices (CDMO), KalVista Pharmaceuticals (KALV), and Neurogene (NGNE). These companies are all part of the "medical" sector.
Adagene (NASDAQ:ADAG) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability.
Adagene currently has a consensus target price of $5.00, suggesting a potential upside of 67.79%. Verastem has a consensus target price of $25.69, suggesting a potential upside of 655.51%. Given Verastem's higher probable upside, analysts clearly believe Verastem is more favorable than Adagene.
Adagene has higher revenue and earnings than Verastem.
Verastem received 580 more outperform votes than Adagene when rated by MarketBeat users. However, 78.26% of users gave Adagene an outperform vote while only 65.28% of users gave Verastem an outperform vote.
9.5% of Adagene shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 2.2% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Adagene's return on equity of 0.00% beat Verastem's return on equity.
Adagene has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
In the previous week, Verastem had 2 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Verastem and 0 mentions for Adagene. Adagene's average media sentiment score of 0.00 equaled Verastem'saverage media sentiment score.
Summary
Adagene beats Verastem on 7 of the 13 factors compared between the two stocks.
Get Adagene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
